Previous 10 | Next 10 |
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress -- Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Unresectable Dedifferentiated Liposarcoma -- -- Third Quarter 2...
Karyopharm Announces Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Unresectable Dedifferentiated Liposarcoma -- Twice-Weekly XPOVIO® (selinexor) Demonstrates a Statistically Significant Reduction in the Ris...
Karyopharm to Report Third Quarter 2020 Financial Results on November 2, 2020 - Conference Call Scheduled for Monday, November 2, 2020, at 4:30 p.m. ET - PR Newswire NEWTON, Mass., Oct. 26, 2020 NEWTON, Mass. , Oct. 26, 2020 /PRNewswire/ -- Karyophar...
Karyopharm Therapeutics Selects MediSpend's Transparency Solution PR Newswire PORTSMOUTH, N.H., Oct. 20, 2020 PORTSMOUTH, N.H. , Oct. 20, 2020 /PRNewswire/ -- MediSpend announced that Karyopharm Therapeutics (NASDAQ: KPTI) selected MediSpend Tr...
WOBURN, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the appointment of Tanya Lewis to its Board of Directors, effective as of No...
Karyopharm Therapeutics (KPTI) presents data from a Phase 2 clinical study evaluating low dose oral selinexor in hospitalized patients with severe COVID-19 at the International Society for Influenza and Other Respiratory Virus Diseases Antiviral Group Virtual Conference on Therapeutics for CO...
Karyopharm Announces Selinexor Clinical Data to be Presented at the International Society for Influenza and Other Respiratory Virus Diseases Antiviral Group Virtual Conference on Therapeutics for COVID-19 − Encouraging Anti-Viral and Anti-Inflammatory Activity Demonstrate...
The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with this Read more ...
NEWTON, Mass. , Sept. 14, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that four abstracts have been selected for poster presentation at the European Society for Medical ...
NEWTON, Mass. , Sept. 2, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Michael Kauffman , MD, PhD, Chief Executive Officer of Karyopharm, will participate in a fireside ch...
News, Short Squeeze, Breakout and More Instantly...
Karyopharm Therapeutics Inc. Company Name:
KPTI Stock Symbol:
NASDAQ Market:
Karyopharm Therapeutics Inc. Website:
Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024 PR Newswire -- Conference Call Scheduled for Tuesday, August 6, 2024 , at 8:00 a.m. ET -- NEWTON, Mass. , July 31, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasd...
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates PR Newswire Long-Term Follow-Up Data Signal Promising Progression-Free S...
Karyopharm to Participate at the Jefferies Global Healthcare Conference PR Newswire NEWTON, Mass. , May 29, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announ...